COVID-19 updates: White House press secretary Jen Psaki tests positive

The five states with the highest death rates over the last week -- Wyoming, Montana, Alaska, West Virginia and Idaho -- are also among the states with the lowest full vaccination rates, according to federal data.

People who have not been fully vaccinated are 6.1 times more likely to test positive for COVID-19 and 11.3 times more likely to die from the virus, according to federal data.

Approximately 63.2 million eligible Americans have yet to get the shot, according to federal data.

But hospitalization rates are continuing to steadily trend down, with just over 51,000 Americans now hospitalized with the virus, compared to 104,000 people hospitalized in late August, according to federal data.

-ABC News' Arielle Mitropoulos

An independent FDA advisory panel on Tuesday will debate and vote on whether to authorize the Pfizer vaccine for children ages 5 to 11. The nonbinding vote is expected between 4:30 p.m. and 5 p.m. ET.

Pfizer data submitted to the FDA has shown that this vaccine, which would be administered to children at one-third of the adult dosage, is nearly 91% effective against symptomatic COVID-19. There were no reported adverse side effects in the clinical trial group.

After the panel votes on whether or not to recommend this vaccine for children 5 to 11, the FDA will make a decision.

Then, the matter heads to the CDC's independent advisory panel to deliberate and vote, which is scheduled for Nov. 2 and Nov. 3. Once the CDC panel votes, CDC Director Rochelle Walensky is expected to make the final sign-off.

The earliest shots could be in arms is the first week of November.

-ABC News' Sasha Pezenik

The past week marked the seventh consecutive week that the United States has seen a drop in pediatric COVID-19 infections since the pandemic peak of nearly 252,000 cases in early September.

Last week, the U.S. reported approximately 118,000 new COVID-19 cases among children, compared to 131,000 cases the previous week, according to a weekly joint report from the American Academy of Pediatrics (AAP) and the Children’s Hospital Association (CHA).

But even with the decline, children still accounted for about a quarter of reported weekly COVID-19 cases. People under the age 18 make up roughly 22% of the U.S. population. Regionally, the Midwest continues to see the highest number of pediatric COVID-19 cases as the area experiences the beginnings of a viral resurgence.

The AAP and CHA wrote in the report that the case rate remains an "extremely high number" of newly diagnosed children, with over 1 million cases added over the past six weeks.

Since the onset of the pandemic, nearly 6.3 million children across the nation have tested positive for COVID-19.

In a similar trend, the rate of pediatric hospital admissions per 100,000 people also continues to decline, alongside other age groups. In the last month, the pediatric hospital admission rate fell by more 43.5%.

Currently, severe illness due to COVID-19 remains "uncommon" among children, the two organizations wrote in the report. According to the nearly two dozen states that reported COVID-19 hospitalizations among children, 0.1% to 2% of all pediatric COVID-19 infections resulted in hospitalization. ​Similarly, in states that reported virus-related deaths by age, 0% to 0.3% of all child COVID-19 cases resulted in death.

However, AAP and CHA warned in the report that there's an urgent need to collect more data on the long-term consequences of the pandemic on children, "including ways the virus may harm the long-term physical health of infected children, as well as its emotional and mental health effects."

Less than 45% of adolescents ages 12 to 17 have been fully vaccinated against COVID-19, according to federal data, and more than 48 million children under 12 remain unvaccinated. But that could soon change, should the Food and Drug Administration and the Centers for Disease Control and Prevention green light COVID-19 vaccinations for kids ages 5 to 11 in the coming weeks.

-ABC News' Arielle Mitropoulos

Moderna announced Tuesday that it will make up to 110 million doses of its COVID-19 vaccine available to African nations at the company's "lowest tiered price."

The Massachusetts-based biotechnology firm said it is prepared to deliver the first 15 million doses by the end of this year, with 35 million doses in the first quarter of 2022 and up to 60 million doses in the second quarter.

"All doses are offered at Moderna’s lowest tiered price," the company said in a press release Tuesday.

Africa, the world's second-largest and second-most populous continent, remains the least-vaccinated region of the world against COVID-19, with just over 5% of its 1.3 billion people fully inoculated.

Moderna CEO Stephane Bancel said the new agreement with the African Union, a continental bloc consisting of the 55 member states that make up the countries of Africa, was facilitated in part by the White House. The deal is separate from the company's agreement with the global vaccine-sharing initiative COVAX to supply up to 500 million doses from late this year through 2022, according to the press release.

"This is the first step in our long-term partnership with the African Union," Bancel said in a statement Tuesday. "We believe our vaccine can play an important role in addressing the needs of low-income countries given its combination of high Phase 3 efficacy against COVID-19, strong durability in the real-world evidence, and superior storage and handling conditions. We recognize that access to COVID-19 vaccines continues to be a challenge in many parts of the world and we remain committed to helping to protect as many people as possible around the globe."

Moderna is also working on plans to allow it to fill doses of its COVID-19 vaccine in Africa as early as 2023, in parallel to building an mRNA vaccine manufacturing facility on the continent with the goal of producing up to 500 million doses each year, according to the press release.